Steven R Schwid
Affiliation: University of Rochester
- Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapSteven R Schwid
Department of Nuerology, University of Rochester, Rochester, New York 14642, USA
Clin Ther 29:2031-48. 2007..Interferon (IFN)-beta therapy represents an important advance in the management of relapsing multiple sclerosis (MS), but information about the relative benefits and risks of available preparations is limited...
- A phase 3 trial of extended release oral dalfampridine in multiple sclerosisAndrew D Goodman
Department of Neurology, University of Rochester Medical Center, Rochester, NY 14642, USA
Ann Neurol 68:494-502. 2010..The current study was designed to confirm efficacy and further define safety and pharmacodynamics...
- A randomized trial of memantine as treatment for spasticity in multiple sclerosisLahar R Mehta
Neuroimmunology Unit, Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA
Mult Scler 16:248-51. 2010..The primary outcome measure for efficacy was the change in Ashworth Spasticity Scale Score. Although well tolerated, memantine treatment did not demonstrate efficacy in treatment of spasticity in this 12-week small exploratory study...
- Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE StudySteven R Schwid
Department of Neurology, University of Rochester, Rochester, NY 14642, USA
Arch Neurol 62:785-92. 2005....
- Broadening the spectrum of controls for skin biopsy in painful neuropathiesDavid N Herrmann
Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
Muscle Nerve 42:436-8. 2010..Distal-leg ENFD/morphology in MS DLLBP patients did not differ significantly from that of healthy controls. This study extends the range of ENFD controls and further supports use of ENFD assessment in SFSN...
- Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trialSteven R Schwid
University of Rochester, Department of Neurology, Rochester, NY 14642, USA
J Neurol Sci 255:57-63. 2007....
- Dose comparison trial of sustained-release fampridine in multiple sclerosisA D Goodman
Multiple Sclerosis Center, Chief Neuroimmunology Unit, Department of Neurology, University of Rochester Medical Center, 601 Elmwood Ave, Room 6 8521, Box 605, Rochester, NY 14642, USA
Neurology 71:1134-41. 2008..To examine the efficacy and safety of three different doses of sustained-release fampridine in people with multiple sclerosis (MS)...
- Immune response to influenza vaccine is maintained in patients with multiple sclerosis receiving interferon beta-1aSteven R Schwid
Department of Neurology, University of Rochester, Rochester, NY, USA
Neurology 65:1964-6. 2005..The two groups were similar in the proportion of patients achieving an HI titer of 40 or greater, the prespecified primary end point and on all secondary indicators of immune response...
- Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trialAndrew D Goodman
University of Rochester, Rochester, NY, USA
Lancet 373:732-8. 2009..This phase III study assessed efficacy and safety of oral, sustained-release fampridine in people with ambulatory deficits due to multiple sclerosis...
- Cognitive fatigue during a test requiring sustained attention: a pilot studySteven R Schwid
Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA
Mult Scler 9:503-8. 2003..Motor fatigue can be objectively measured as the decline in strength occurring during sustained contractions. Analogous declines in cognitive performance occur during tasks requiring sustained attention...
- Polyunsaturated fatty acids and their potential therapeutic role in multiple sclerosisLahar R Mehta
Neuroimmunology Unit, University of Rochester Medical Center, 601 Elmwood Avenue, Box 605, Rochester, NY 14586, USA
Nat Clin Pract Neurol 5:82-92. 2009..We propose that the potential role of PUFAs as disease-modifying, anti-inflammatory treatments for MS should be revisited in proof-of-concept trials that use accepted MRI outcome measures...
- Cancer incidence in a trial of an antiapoptotic agent for Parkinson's diseaseSteven R Schwid
Department of Neurology, University of Rochester, Rochester, New York, USA
Mov Disord 25:1801-8. 2010..Melanoma occurrence in our PD patients was greater than predicted compared with the general population and was unrelated to dopaminergic therapy. Clinical surveillance of PD patients for melanoma may be warranted...
- Pain associated with multiple sclerosis: systematic review and proposed classificationAlec B O'Connor
Department of Medicine, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Rochester, NY 14642, USA
Pain 137:96-111. 2008..Suggestions for future studies that would increase understanding of the natural history, mechanisms, and treatment of pain in patients with MS are presented...
- Neuromyelitis optica spectrum disorder in a patient with systemic lupus erythematosus and anti-phospholipid antibody syndromeLahar R Mehta
Neuroimmunology Unit, Department of Neurology, University of Rochester Medical Center, Rochester, NY 14642, USA
Mult Scler 14:425-7. 2008....
- A randomized controlled study of the acute and chronic effects of cooling therapy for MSSteven R Schwid
University of Rochester, Rochester, NY, USA
Neurology 60:1955-60. 2003..CONCLUSIONS: Cooling therapy was associated with objectively measurable but modest improvements in motor and visual function as well as persistent subjective benefits...
- Serum urate as a predictor of clinical and radiographic progression in Parkinson diseaseMichael A Schwarzschild
MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Boston, USA
Arch Neurol 65:716-23. 2008..To determine whether concentration of serum urate, a purine metabolite and potent antioxidant that has been linked to a reduced risk of Parkinson disease (PD), predicts prognosis in PD...
- Treating fatigue in patients with MS: one step forward, one step backSteven R Schwid
Neurology 64:1111-2. 2005
- Fatigue in multiple sclerosis: current understanding and future directionsSteven R Schwid
Department of Neurology, University of Rochester Medical Center, NY, USA
J Rehabil Res Dev 39:211-24. 2002..Dividing fatigue into these components can provide objective assessments that are less likely to be confounded by other symptoms of MS, such as weakness, spasticity, cognitive impairment, and depressed mood...
- Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagilineJ Antonelle deMarcaida
Department of Neurology, University of Connecticut, Farmington, Connecticut, USA
Mov Disord 21:1716-21. 2006..These data demonstrate that rasagiline 0.5 to 2 mg daily is not associated with clinically significant tyramine reactions and can be used as monotherapy or adjunct to levodopa in PD patients without specific dietary tyramine restriction...
- Futility studies: spending a little to save a lotSteven R Schwid
Neurology 66:626-7. 2006
- Multiple sclerosis, depression, and the risk of suicideEric D Caine
Neurology 59:662-3. 2002